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T he word "epigenetics" is composed of a
Greek prefix, "epi," meaning "upon," "on,"
or "around" and the word "genetics." Therefore, epigenetics can be defined as the mechanism that affects heritable changes in gene expression and function without alternating the sequence of Epigenetic regulation can be classified at 4 different molecular levels: 1) DNA methylation, 2) posttranslational modifications of histones, 3) adenoisine triphosphate (ATP)-dependent chromatin conformation and remodeling, and 4) non-coding RNAs. In this review, we will summarize the recent advances and provide an overview of the epigenomics studies focusing on HF in humans and animal models.
DNA METHYLATION: A POTENTIAL BIOMARKER FOR HF
The methylation of DNA in eukaryotes predominantly occurs at the fifth carbon of the pyrimidine ring of the not necessarily represent the official views of the NIH. Dr. Tang has a financial relationship with Sequana Medical Inc. and MyoKardis Inc. Dr. Liu has reported that she does not have any relationships relevant to the contents of this paper to disclose. cytosine (5mC) and followed by a guanine dinucleotide where cytosine and guanine are separated by a phosphate (CpG). DNA methylation plays a crucial role in gene regulation, particularly on transcriptional repression that depends on where methylation is located. Increased methylation of CpG-enriched regions, known as CpG islands (CGI) at the promoter region of genes, is often associated with gene silencing, whereas methylated CpG found in the gene body is usually related to gene activation (1) .
In many pathological conditions, particularly in the cancer genome, alteration of DNA methylation of genes is the first epigenetic hallmark associated with the disease process (2) . For example, a typical signature in many types of cancer cells is the hypermethylation at CGI of tumor suppressor genes causing transcriptional silencing of these genes. The silencing of these tumor suppressor genes affects the progression of the tumorigenesis (3) .
The pioneering genome-wide studies on DNA methylation in the failing human myocardium were performed a decade ago (4, 5) . Movassagh et al. first demonstrated that a large population of CGI and promoters were hypomethylated in the end-stage failing heart, and such differential DNA methylation patterns correlated with differential expression of angiogenic factors (4) . Using methylated DNA immunoprecipitation followed by sequencing, they determined that the differential DNA methylation between non-failing and end-stage failing hearts did not occur evenly across the genome, but concentrated at promoter CGIs, intragenic CGIs, and gene bodies (5) . In 2013, Haas et al. identified a set of candidate genes with altered DNA methylation status that may be involved in HF by using a lower-resolution method (6) . Among these candidate genes, 2 genes displayed differential gene expression in dilated cardiomyopathy (DCM): adenosine receptor A2A (Adora2A) and lymphocyte antigen 75 (Ly75) . Interestingly, when they validated these 2 genes by knockdown either Ly75 or Adora2A using morpholino in zebrafish, both morphants (zebrafish mutants) developed severe HF similar to that observed in humans (6) .
A more extensive human study on DNA methylation in HF was published recently. Meder et al. generated a genome-wide DNA methylation profile in patients with DCM and in donor left-ventricular biopsies and whole peripheral blood using a high-resolution epigenomic-wide method with a large cohort (7) . They identified 59 CpG loci with significant changes in DNA methylation in the myocardium of patients with DCM compared with clinical controls. Among these CpG loci, 29 and 30 were hypomethylated and hypermethylated in DCM, respectively. Using multi-omics approaches, they linked a subset of 517 epigenetic loci with DCM and cardiac gene expression. By further examining the methylome of peripheral blood cells, a differential display of 217 methylation sites between controls and patients with DCM was observed. Moreover, when they compared methylome between myocardium and peripheral blood cells, they identified distinct epigenetic methylation patterns that are conserved between 2 tissues. For example, the NPPA (natriuretic peptide A, also known as ANP) and NPPB (natriuretic peptide B, also known as BNP) loci were demethylated in DNA in heart tissues and peripheral blood cells from patients with DCM (7) .
Using a cell-sorting technique coupled with a whole-genome bisulfite sequencing approach, Gilsbach et al. showed that only a few genomic regions within gene body of 6 genes exhibited differential DNA methylation between non-failing and failing human cardiomyocytes (8) . However, those genes did not express differentially between the 2 groups. Additionally, the global DNA methylation patterns are not significantly different between non-failing and failing cardiomyocytes. Therefore, the authors concluded that methylated CpG is relatively stable in chronic HF (8) . However, this observation differs from other studies in which more differential DNA methylated regions and gene loci were identified. In fact, Meder et al. found 59 differential CpG regions in DCM comparing to non-failing hearts from a total of 72 left ventricular biopsies. Moreover, a recent study by Glezeva et al. using capture-based bisulfite sequencing method also identified 151 differential methylation regions in DCM in comparison with non-failing hearts (9) . Such discrepant findings in DNA methylation patterns in the failing heart could be due to the different technologies for DNA methylation that were used in studies (whole genome bisulfite sequencing [WGBS] vs. bead array vs. capture-based bisulfite sequencing).
Another reason could be that the study by Gilsbach et al. (8) used sorted cardiomyocytes whereas other studies used bulk left ventricle tissues (4, 5, 7, 9) , and Epigenetic Regulation of HF D E C E M B E R 2 0 1 9 : 9 7 6 -9 3 end-stage ischemic cardiomyopathy (ICM). They also identified the differential DNA methylation between ICM and non-ischemic cardiomyopathy (NICM) (10).
Specifically, the authors observed that 12.6% of CpG sites were differentially methylated between ICM and NICM, and that hypermethylation within promoter- were associated with these DMRs (9) . Further validation for the genes associated with these DMRs confirmed that 6 protein-coding genes and 2 microRNA (miRNA) displayed significantly altered gene expression in at least 1 of the disease groups comparing with the control group. Among them, 2 novel HOCM-related genes were identified from this study, namely HEY2 and MSR1. Both gene loci were hypermethylated in patients with HOCM, and their gene expression level was reduced. In addition, 2 genes involved in the regulation of the extracellular matrix, CTGF and MMP2, were found to be hypomethylated with increased gene expression level in DCM. Moreover, COX17, MYMO3, and miR24-1 were found to be hypermethylated with reduced gene expression, whereas CTGF miR155 was hypomethylated with elevated gene expression in ICM (9) . The PTMs of histones and their roles during cardiomyocyte differentiation and heart development for tissue regeneration have been studied extensively (14) (15) (16) (17) (18) . However, our understanding of these regulations in HF remains unclear. The PTMs of histones is achieved by the actions of histone "writers" and "erasers." They are enzymes that either add (write) PTM to histones or remove (erase) PTM from the histone proteins. Currently, the best understood the regulation of PTM on histones is on acetylation, methylation, phosphorylation (19) . In this review, we will focus on 2 major PTMs to histone proteinsmethylation and acetylation. cKO mouse hearts (32) .
POST-TRANSLATIONAL MODIFICATIONS
Moreover, a recent study showed that G9a/EHMT2, another HMT, was found to be required for cardiomyocyte homeostasis to silence the fetal gene program in the adult heart (33 identified that the level of histone acetylations (e.g., H3K9ac and H3K27ac) was decreased around the gene loci whose expression was down-regulated in TAC mice (37) . In addition, there was a correlation be- Consistent with this finding, H19 was later shown to be a negative regulator of cardiomyocyte hypertrophy (76) . Another interesting lncRNA from their findings is a cardiac hypertrophy-associated epigenetic regulator (Chaer), which is a heart-enriched lncRNA (77) .
Chaer was shown to be involved in cardiac hypertrophy development by directly binding to the catalytic subunit of polycomb repressor complex 2 (PRC2).
PRC2 is responsible for methylation of H3K27me3 for gene silencing. The interaction between Chaer and PRC2 decreased the level of H3K27me3 in the promoter region of cardiac hypertrophy-related genes, such as NPPA. Therefore, it may cause induction of these cardiac hypertrophy-related genes in hypertrophy hearts (77) . Epigenetic Regulation of HF (93, 94) . In addition, it was shown that the deficiency on dietary methyl-donors had a great impact on the epigenetic profile and also resulted in the development of metabolic diseases (95) . However, the link between the gut microbiomeproduced folate to HF remains unclear.
Choline is another methyl-group donor for epigenetic modification and is an essential nutrient.
Choline is not only used by the host but also by the bacteria residing in the intestine of the host. Gut A DNA methylation inhibitor, 5-azacytidine (5aza), is widely used to treat leukemia and sickle cell diseases (113, 114) . In a spontaneously hypertensive rat model, intraperitoneal injection of 5-aza at a dose of 10 mg/kg resulted in improvement in cardiac function as well as reduction in cardiac fibrosis (115).
Last but not least, lncRNA silencing approach using GapmeR, a type of antisense oligonucleotide, is another potential therapeutic target for HF (116) . 
